Walmart Sees Impact from Appetite-Suppressing Meds

By Patricia Miller


In this article

  • Loading...
  • Want to see what you should be buying? Check out our top picks.

Appetite-suppressing drugs reshape retail. Invest wisely with insights into changing consumer behavior.

Shopping trolley holding Ozempic drug 1mg next to packet of meds.
Pharma's Diet Drugs Reshaping Retail Habits

TL: DR - What You Need To Know

Walmart Inc. (NYSE: WMT) has noticed a subtle shift in shopping habits related to the use of appetite-suppressing medications, including the diabetes drug Ozempic and Wegovy. According to John Furner, CEO of Walmart's US operation, there is a slight reduction in overall shopping basket contents, with fewer units and slightly fewer calories being purchased by those taking these drugs.

The retailer is closely examining sales patterns using anonymized data on shoppers and comparing the habits of drug users to those who aren't taking such medications. However, it's too early to make any definitive conclusions about the impact of these drugs, including those made by Novo Nordisk A/S.

This trend of weight-loss drugs influencing consumer behavior has gained attention from CEOs and investors across various industries. For example, the CEO of Kellanova, the company behind Pringles and Cheez-Its, is also studying the potential effects of these drugs on dietary behaviors.

Walmart, which sells GLP-1 drugs, including Ozempic, through its pharmacies, has experienced a significant revenue boost from these medications, with US sales growing by 300% between 2020 and 2022.

Walmart's CEO, Doug McMillon, anticipates continued growth in food, consumables, and health and wellness products, primarily due to the popularity of GLP-1 drugs in the latter half of the year.

Why This Is Important for Retail Investors

  1. Investment Implications: Retail investors should be aware of how the use of appetite-suppressing medications impacts retailers like Walmart. Changes in consumer behavior can have a direct influence on the company's financial performance, which, in turn, affects its stock price. Retail investors may consider this information when making investment decisions related to Walmart's stock.

  2. Consumer Trends: Understanding shifts in shopping habits driven by medication usage provides retail investors with insights into broader consumer trends. This knowledge can be valuable when assessing the health of the retail sector as a whole, helping investors make informed decisions about their retail-focused investments beyond just Walmart.

  3. Competitive Landscape: Retail investors should monitor how Walmart and its competitors respond to these trends. If one retailer adapts better to changing consumer preferences related to appetite-suppressing medications, it could gain a competitive edge in the market. This could impact market share and profitability, influencing stock performance.

  4. Long-term Investment Strategy: For retail investors with a long-term investment horizon, recognizing the potential impact of healthcare trends on retail can help them make strategic decisions. They can choose to invest in companies that are well-positioned to adapt to changing consumer behavior and healthcare developments, ensuring the long-term viability of their investments.

How Can You Use This Information?

Walmart generally serves as a reliable bellwether for the broader US consumer sentiment and spending trends. Here are some of the investing ideas that can be explored using this information:

Growth Investing

  • Consider investing in pharmaceutical companies that produce these medications, especially if their sales are rapidly growing. The potential for increased sales and market share in this niche could signify growth opportunities.

  • Evaluate retail companies that are quick to adapt to consumer trends influenced by these drugs. Retailers that successfully integrate and market health and wellness products could experience growth in their revenue and stock prices.

Momentum Investing

  • Monitor the momentum of pharmaceutical stocks that produce these drugs. If there is strong upward momentum due to increasing demand for these medications, it may be an attractive short-term investment.

  • Watch for retail stocks with positive momentum driven by their ability to cater to consumers using these drugs. Positive earnings reports and increasing sales could be indicators of momentum-worthy stocks.

Sector Rotation

  • Consider sector rotation strategies by moving between sectors that are performing well and those that are enduring some pressure. When trends shift, rebalance your portfolio accordingly.

  • Employ a defensive approach by allocating more to healthcare during economic downturns when consumers may prioritize health and wellness, potentially benefiting pharmaceutical companies.

Long-Term Health Trends

  • Recognize the long-term health and wellness trend as an overarching investment theme. Invest in companies across various sectors, such as pharmaceuticals, healthcare, and wellness-focused retailers, to capitalize on the broader shift toward healthier lifestyles.


  • Diversify your portfolio by including a mix of stocks from different sectors that may be affected by these medications. This reduces risk by not overcommitting to a single investment theme.

Risk Management

  • Be cautious about potential regulatory changes that may impact the pharmaceutical industry or retail sector, especially if new regulations affect the availability or pricing of these medications. Diversification can help mitigate such risks.

Read What Others Are Saying

What you should read next:

Explore more on these topics:



This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Patricia Miller does not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above article.

Patricia Miller has not been paid to produce this piece by the company or companies mentioned above.

Digitonic Ltd, the owner of, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.

Digitonic Ltd, the owner of, has not been paid for the production of this piece by the company or companies mentioned above.

Sign up for Investing Intel Newsletter